Results 51 to 60 of about 17,468,048 (391)

Current perspective of venous thrombosis in the upper\ud extremity [PDF]

open access: yes, 2008
Venous thrombosis of the upper extremity is a rare disease. Therefore, not as much is known about risk factors, treatment and the risk of recurrence as for venous thrombosis of the leg.
Doggen, C.J.M.   +3 more
core   +3 more sources

Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment

open access: yesAdvanced Science, EarlyView.
A novel melanin‐based therapeutic composed of ultrasmall polydopamine nanodots is employed as an efficient oral formulation for the targeted treatment of inflammatory bowel disease. The potential therapeutic mechanism of polydopamine nanodots mainly involves the elimination of excessive oxidative stress, the reduction of ROS‐mediated proinflammatory ...
Zhen Ding   +11 more
wiley   +1 more source

Association between PT, PT-INR, and in-hospital mortality in critically ill patients with tumors: A retrospective cohort study

open access: yesFrontiers in Public Health, 2023
ObjectivesProthrombin time (PT) and PT-INR are independent predictors of mortality in patients with cancer. The PT and PT-INR of cancer patients are independent predictive variables of mortality.
Jia-Dong Liang   +12 more
doaj   +1 more source

Abnormal prothrombin (DES-y-Carboxy Prothrombin) in hepatocellular carcinoma [PDF]

open access: yes, 1991
Des-γ-carboxy prothrombin (DCP), a protein induced by vitamin K absence or antagonist-II (PIVKA-II) was measured by an enzyme immunoassay (E-1023) using anti-DCP monoclonal antibody in 92 patients with various hepatobiliary diseases. Thirty-six of the 38
Carr, B   +5 more
core  

Timing and volume of fluid administration for patients with bleeding [PDF]

open access: yes, 2003
Original article can be found at: http://www3.interscience.wiley.com Copyright John Wiley & Sons. ‘This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2003, Issue 3.
Bunn, Frances, Kwan, I., Roberts, I.
core   +1 more source

Evaluation of a Prolonged Prothrombin Time [PDF]

open access: yesClinical Chemistry, 2008
A 47-year-old African American woman was evaluated for a prolonged prothrombin time (PT) result obtained before she underwent right total hip arthroplasty. The patient had no history of gastrointestinal or intracranial bleeding, epistaxis, or hemarthrosis.
Joshua L, Hood, Charles S, Eby
openaire   +2 more sources

Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles

open access: yesAdvanced Science, EarlyView.
This study presents heparin‐derived nanoparticles (HP‐NPs) as a novel precision medicine platform that combines therapeutic and delivery functions. HP‐NPs target drug‐resistant glioblastoma stem cells, reprogramming them into a drug‐sensitive phenotype and significantly reducing tumor progression.
Vadim Le Joncour   +14 more
wiley   +1 more source

Effect of Hypoxic Ischaemic Encephalopathy on Coagulation Profile in Neonates in a Tertiary Care Center, Agra- A Prospective Clinical Study

open access: yesIndian Journal of Neonatal Medicine and Research, 2023
Introduction: Perinatal asphyxia is very common in developing countries. Coagulopathy occurs as a part of spectrum of multiorgan dysfunction following hypoxic insult.
Payal Mittal   +3 more
doaj   +1 more source

An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin

open access: yesAdvanced Science, EarlyView.
By simply conjugating thrombin's active‐site inhibitor, dabigatran, with an exosite inhibitor, aptamer HD1, the resulting EXosite‐ACTive site (EXACT) inhibitors show two orders of magnitude higher potency and selectivity via synergistic binding, while maintaining the aptamer's antidote‐reversible trait, yielding a potential substitute for the animal ...
Haixiang Yu   +11 more
wiley   +1 more source

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban

open access: yesPharmaceutics, 2019
Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-
Minsoo Kim   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy